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Summary
Acute graft-versus-host disease (aGVHD) is a life-threatening complication
following allogeneic haematopoietic stem cell transplantation (HSCT),
occurring in up to 30–50% of patients who receive human leucocyte antigen
(HLA)-matched sibling transplants. Current therapies for steroid refractory
aGVHD are limited, with the prognosis of patients suboptimal. Mesenchy-
mal stem or stromal cells (MSC), a heterogeneous cell population present in
many tissues, display potent immunomodulatory abilities. Autologous and
allogeneic ex-vivo expanded human MSC have been utilized to treat aGVHD
with promising results, but the mechanisms of therapeutic action remain
unclear. Here a robust humanized mouse model of aGVHD based on deliv-
ery of human peripheral blood mononuclear cells (PBMC) to non-obese dia-
betic (NOD)-severe combined immunodeficient (SCID) interleukin (IL)-
2rgnull (NSG) mice was developed that allowed the exploration of the role of
MSC in cell therapy. MSC therapy resulted in the reduction of liver and gut
pathology and significantly increased survival. Protection was dependent
upon the timing of MSC therapy, with conventional MSC proving effective
only after delayed administration. In contrast, interferon (IFN)-g-stimulated
MSC were effective when delivered with PBMC. The beneficial effect of MSC
therapy in this model was not due to the inhibition of donor PBMC chimer-
ism, as CD45+ and T cells engrafted successfully in this model. MSC therapy
did not induce donor T cell anergy, FoxP3+ T regulatory cells or cause PBMC
apoptosis in this model; however, it was associated with the direct inhibition
of donor CD4+ T cell proliferation and reduction of human tumour necrosis
factor-a in serum.
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Introduction
Allogeneic haematopoietic stem cell transplantation
(HSCT) has become widely used for the treatment of hae-
matological malignancies and inherited blood disorders
[1]. However, the development of acute graft-versus-host
disease (aGVHD) is a life-threatening complication
following allogeneic HSCT. GVHD can occur in up to
30–50% of patients who receive human leucocyte antigen
(HLA)-matched sibling transplants and more frequently in
HLA-mismatched, unrelated donor transplants [2]. In
order for GVHD to occur, the donor graft must contain
immune-competent T cells, be transplanted into a recipi-
ent unable to mount a successful immune response against
the graft, and the recipient must express tissue antigens
not present in the donor transplant [3]. The standard
first-line therapy for aGVHD focuses on the suppres-
sion of donor T cells through the administration of
glucocorticosteroids combined with immunosuppressive
drugs, such as cyclosporin A or tacrolimus [4]. Steroid
therapies have improved the outcome and increased sur-
vival of many patients with aGVHD [5–7]. Nevertheless,
the prognosis for steroid refractory aGVHD patients
remains very poor, with a 5-year survival rate as low
as 30% [2,8]. In these cases, a second-line therapy is
required.
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Mesenchymal stem or stromal cells (MSC) are a hetero-
geneous pericyte-like cell population present in bone
marrow, adipose, cord blood and other tissues [9,10]. MSC
form plastic adherent colonies in vitro and are capable of
osteocyte, adipocyte and chondrogenic differentiation
[11,12]. These cells are potential agents for regenerative
medicine [13], and act through the secretion of ‘trophic
factors’ that promote repair through the recruitment and
activation of other reparative cells. MSC may also act
through cytoprotective mechanisms or by immune suppres-
sion [13,14]. In vitro, MSC have a direct suppressive effect
on T and B lymphocytes, natural killer (NK) cells and sup-
porting dendritic cell (DC) functions [15–21]. The combi-
nation of immunoregulatory and regenerative properties
suggest a potential role for MSC in the therapeutic induc-
tion of immune tolerance. To this effect, there has been
interest in the use of MSC as a cell therapy for a number of
inflammatory conditions, such as Crohn’s disease, multiple
sclerosis and aGVHD [22–25].
Autologous and allogeneic ex-vivo expanded human
MSC have been utilized in studies of haematological disor-
ders, with promising results. Le Blanc et al. demonstrated
the potential for MSC infusion to treat steroid-refractory
GVHD of the gut and liver, showing no reactivity between
the haploidentical MSC and recipient lymphocytes [26],
and this was extended to MSC from mismatched unrelated
donors [24]. However, the initial optimism for MSC as a
cell therapy for aGVHD has become tempered by recent
clinical trials. While MSC proved safe and beneficial follow-
ing infusion to patients with aGVHD in a Phase II trial
[25], a Phase III trial for steroid-refractory aGVHD dem-
onstrated no statistical difference between MSC or the
placebo groups in relation to achievement of complete
response within 28 days of initiating treatment [27,28].
However, it is important to note that beneficial effects were
observed in this Phase III study for the treatment of
aGVHD of the gut and liver, but not of the skin. These per-
plexing data highlight the need for more refined models for
examining the exact mechanisms of disease modulation by
human MSC.
The use of mouse models offers a feasible alternative to
human observations, when hypothesis-driven studies are
needed, but mouse-in-mouse systems do not always reflect
the pathology of human diseases. In many aGVHD
models, the effector cell is based on infusion of murine
splenocytes which may behave differently to human effec-
tor cells; furthermore, conventional mice are not well
aligned to the study of human cell therapy products. The
introduction of the interleukin (IL)-2 receptor gamma
mutation onto the non-obese diabetic (NOD)-severe com-
promised immunodeficient (SCID) background has
allowed for the development of refined mouse models.
NOD-SCID IL-2rgnull (NSG) mice are deficient for T, B and
NK cell activity and allow engraftment of high levels of
human peripheral blood mononuclear cells (PBMC) [29].
The NSG model offers an opportunity to examine human
donor cells in combination with clinical cell therapeutics.
Using a humanized NSG mouse model of aGVHD, this
study sought to examine the effect of human MSC cell
therapy, and to investigate the possible therapeutic mecha-
nisms involved. Human MSC cell therapy significantly
prolonged the survival of NSG mice with aGVHD, reduc-
ing target organ pathology. MSC therapy did not interfere
with donor PBMC engraftment or involve the induction of
donor T cell apoptosis, anergy or regulatory cell expan-
sion, but rather the direct inhibition of both donor CD4+
T cell proliferation and tumour necrosis factor (TNF)-a
production.
Materials and methods
A xenogeneic aGVHD model
All procedures involving animals or human material were
carried out by licensed personnel according to approved
guidelines. Ethical approval for all work was received from
the ethics committee of National University of Ireland
(NUI) Maynooth. A humanized mouse model of aGVHD
was adapted and optimized from a protocol described
by Pearson et al. [29]. NOD.Cg-PrkdcscidIL2tmlWjl/Szj mice
(NOD-SCID IL-2rgnull) (NSG) (Jackson Laboratories, Bar
Harbour, ME, USA) were exposed to a conditioning dose of
2·4 Gray (Gy) of whole-body gamma irradiation. Human
PBMC from healthy volunteer donors were isolated by
Ficoll-density centrifugation and administered intrave-
nously (i.v.) to NSG mice (6·3 ¥ 105 g-1) via the tail vein 4 h
following irradiation. Negative control mice received a
sham infusion of phosphate-buffered saline (PBS) alone.
Signs of aGVHD occurred typically between days 12 and
15 post-PBMC transfusion. In some mice, conventional
human mesenchymal stem cell (MSC) (4·4 ¥ 104 g-1)
therapy was administered on day 7 post-PBMC transfusion.
In other groups, interferon (IFN)-g stimulated MSC
(4·4 ¥ 104 g-1) were administered concurrent with PBMC on
day 0. The level of human cell chimerism was analysed by
flow cytometry (days 4, 8 and 12), examining the expression
of CD45+ cells and the ratios between human CD4 and CD8
T cells. aGVHD development was determined by examining
features daily including body weight, ruffled fur, locomotor
activity, posture and diarrhoea. Animals that displayed
greater than 15% total body weight loss or a pathological
score of 8 were killed humanely according to local ethical
committee guidelines. Upon aGVHD development in the
group of mice receiving PBMC alone (positive control)
(days 12–15), target organs and sera were harvested from all
groups for histological analysis, serum analysis and cell
characterization. All experiments were repeated two or
more times with five to seven mice per group on each
occasion.
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Histopathological analysis and scoring
Target organs (lung, liver and gut) were recovered from
mice (days 12 or 15) and fixed in 10% (v/v) buffered forma-
lin, processed for histology and embedded in paraffin wax.
Five-mm tissue sections were stained by haematoxylin and
eosin (H&E) and coded without reference to prior treat-
ment, blinded and then examined by two independent
observers. A semi-quantitative scoring system was used to
assess abnormalities in the lung, liver and gastrointestinal
tract (GI) tract [30–32].
Human mesenchymal stem cell isolation and culture
Human bone marrow mesenchymal stem cells were gener-
ated as previously described [33] in collaboration with the
Regenerative Medicine Institute (REMEDI, NUI Galway,
Ireland). Briefly, bone marrow aspirates were taken from
the iliac crest of healthy consenting adult donor patients
according to an approved clinical protocol [34]. Human
MSC batches used in this study conformed to the Interna-
tional Society for Cellular Therapy (ISCT) criteria [16] and
were capable of differentiation to adipocytes, osteocytes and
chondrocytes and were only used at low passage (3–8).
Human MSC were cultured in complete Dulbecco’s modi-
fied Eagle’s medium (DMEM) (Invitrogen-Gibco, Dublin,
Ireland) supplemented with 10 % (v/v) fetal bovine serum
(FBS), 200 U/ml penicillin and 200 mg/ml streptomycin. In
some instances, MSC were stimulated with recombinant
human IFN-g (500 U/ml) (Peprotech, London, UK) for
48 h and washed extensively with PBS prior to their use in
vitro or in vivo.
Assessment of MSC-induced T cell apoptosis in vitro
and in vivo
For in-vitro apoptosis, PBMC (0·5 ¥ 106/ml) were co-
cultured with MSC (1·5 ¥ 105/ml) in complete RPMI
(cRPMI) in the presence or absence of 500 mg/ml cisplatin
(control) (Sigma-Aldrich, Arklow, Ireland). After 24 h,
PBMC were recovered by gentle aspiration from adherent
MSC and apoptosis was detected by annexin V/propidium
iodide (PI) staining (BD Biosciences, Oxford, UK), meas-
ured by flow cytometry using a BD fluorescence activated
cell sorter (FACS)Calibur cytometer with CellQuest soft-
ware (BD Biosciences).
For in-vivo apoptosis, in order to optimize, first, the
detection of apoptosis FAM-FLIVO™ green dye (Immuno-
chemistry Technologies, Bloomington, MN, USA) was used.
As a control for the detection of FLIVO in vivo, BALB/c
mice were irradiated lethally with 12 Gy gamma irradiation.
After 24 h, 8 mg (100 ml) of FAM-FLIVO™ green dye was
injected per mouse and left to circulate for 1 h. After 1 h
(or other times, not shown), the liver was harvested and
isolated cells were analysed by flow cytometry to verify
detectability of apoptosis in vivo. To assess potential
MSC-induced apoptosis following cell therapy, PBMC
(6·3 ¥ 105g-1) and/or IFN-g stimulated MSC (4·4 ¥ 104 g-1)
were delivered via the tail vein to 2·4 Gy-irradiated NSG
mice on day 0. On day 12 (or days 1 and 5, data not shown),
8 mg (100 ml) of FAM-FLIVO™ green dye (Immunochemis-
try Technologies) was injected per mouse and left to circu-
late for 1 h. The lungs and livers were harvested and cells
isolated following collagenase (300 U/ml) (Sigma-Aldrich)
and DNase I (10 mg/ml) digestion (Roche Diagnostics,
West Sussex, UK). Cells were counterstained with anti-
human CD4 allophycocyanin (APC) (eBioscience, San
Diego, CA, USA) and analysed by flow cytometry.
Assessment of human MSC-induced lymphocyte
anergy and proliferation
Bone marrow-derived dendritic cells (DC) were isolated
from BALB/c mice and cultured in cRPMI supplemented
with 20 ng/ml granulocyte–macrophage colony-stimulating
factor (GM-CSF) (Peprotech) for 8 days. Human CD4+ T
cells were isolated from PBMC by magnetic bead separa-
tion following the manufacturer’s guidelines (R&D Sys-
tems, Minneapolis, MN, USA). Murine DC (1·5 ¥ 105/ml)
were matured following stimulation with polyinosinic-
polycytidylic acid (polyIC) (20 mg/ml), as described previ-
ously [35], and co-cultured with human CD4+ T cells
(1 ¥ 106/ml) in the presence or absence of human MSC
(1 ¥ 105/ml) in cRPMI supplemented with 0·1% (v/v) beta-
mercaptoethanol. After 5 days, human CD4+ T cell were
repurified from co-cultures by CD4+ magnetic bead separa-
tion and allowed to rest for 24 h in cRPMI. Repurified
human CD4+ T cells (1 ¥ 106/ml) were then co-cultured
with irradiated BALB/c DC (1 ¥ 105/ml) and stimulated
with polyIC (20 mg/ml) in the presence or absence of
recombinant human IL-2 (rhIL-2) (100 U/ml) for 72 h and
proliferation was assessed.
In-vitro proliferation was determined by culture of
human PBMC (1 ¥ 106 cells/ml) in the presence or absence
of human MSC (1 ¥ 105 cells/ml) in cRPMI. In mitogen-
driven assays, cultures were stimulated with phytohaemag-
glutinin (PHA) (Sigma-Aldrich) at 5 mg/ml. Cell culture
supernatants were sampled for the presence of human
TNF-a and IFN-g by enzyme-linked immunosorbent assay
(ELISA) (R&D Systems). After 72 h, [3H]-thymidine (Amer-
sham Biosciences, Buckinghamshire, UK) at 0·5 mCi/ml was
added. Cultures were harvested 6 h later using an automatic
cell harvester and radioactive incorporation, assessed as
previously described [16,36].
In-vivo proliferation was measured by labelling human
PBMC with 10 mM carboxyfluorescein succinimidyl ester
(CFSE) (Invitrogen), washed twice with PBS and adminis-
tered at 6·3 ¥ 105 g-1 to irradiated NSG mice on day
0. IFN-g-stimulated MSC (4·4 ¥ 104 g-1) were delivered
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concurrently with PBMC on day 0. After 5 days the lungs,
livers and spleens were harvested from each mouse. A
single-cell suspension of 1 ¥ 106 cells/ml was counterla-
belled with anti-human CD4 APC for 15 min at 4°C. Cells
were analysed for CFSE staining and the expression of
human CD4 by flow cytometry.
Detection of human FoxP3 expression
Forkhead box protein 3 (FoxP3) expression in vitro was
assessed using whole unsorted PBMC (0·5 ¥ 106/ml), or
with CD4+ CD25- or CD4+ CD25+ sorted T cells (FACS Aria
BD). These populations were then co-cultured with MSC
(1·5 ¥ 105/ml) for 72 h in cRPMI. PBMC or sorted CD4+ T
cells were recovered from culture by gentle aspiration from
adherent MSC and examined by flow cytometry. Cells were
washed in PBS, surface-stained for CD4 APC and CD25
phycoerythrin (PE) where required. Cells were then fixed in
2% (v/v) paraformaldehyde, permeabilized in PBS/Tween
and blocked using normal rat serum. Following this, cells
were incubated with anti-human FoxP3 fluorescein isothio-
cyanate (FITC) (eBioscience) for 30 min at 4°C. Cells were
washed, fixed in 1% (v/v) formaldehyde/PBS and analysed
by flow cytometry within 4 h.
Regulatory T cell (Treg) induction in vivo was examined in
the aGVHD model described above with either IFN-g-
stimulated MSC (4·4 ¥ 104 g-1) administered i.v on day 0 or
non-stimulated MSC (4·4 ¥ 104 g-1) on day 7 post-PBMC
transfusion. On day 12, the day of aGVHD pathology mani-
festation, the lungs, livers and spleens of NSG mice were
harvested and a single-cell suspension prepared. The surface
expression of human CD4 APC, CD25 PE and intracellular
expression of human FoxP3 FITC was determined by flow
cytometry.
Statistical methods
Statistical analysis was performed using GraphPad Prism™
software (GraphPad, San Diego, CA, USA). The Student’s
paired t-test was used when statistical analysis was required
between two experimental groups. One-way analysis of
variance (anova) was used to test for statistically significant
difference when multiple experimental groups were com-
pared. Kaplan–Meier curves (log-rank test) were used to
compare survival between treatment groups. Data are pre-
sented as  standard error of the mean (s.e.m.). P-values of
P < 0·05 (*), P < 0·01 (**) or P < 0·001 (***) were consid-
ered statistically significant.
Results
Human MSC reduce aGVHD pathology and prolong
survival in a humanized mouse model
A robust and reproducible model of aGVHD was
established in NSG mice by delivery of human PBMC.
This was adapted from Pearson et al. [29], and reproduc-
ibility achieved by (i) normalizing PBMC dose to murine
body weight, (ii) use of freshly isolated PBMC from
healthy donors and (iii) preconditioning of mice by
exposure to 2·4 Gy irradiation prior to PBMC delivery.
On day 7 post-PBMC transfusion, human MSC allogeneic
to the PBMC donor were given i.v. as a cell therapy.
NSG mice that received PBS alone did not develop any
signs of aGVHD, whereas mice that received PBMC
developed aGVHD consistently between days 12 and 15,
with weight loss, hunched posture, ruffled fur and reduced
locomotion (Fig. 1a,b). Delivery of non-stimulated human
MSC on day 0 had no detectable beneficial effect (data
not shown); however, MSC therapy on day 7 significantly
extended the survival of NSG mice with aGVHD
(P < 0·0001), with some mice surviving for more than 30
days (Fig. 1c).
The livers of NSG mice that received PBS as a control
appeared normal, with no cell infiltration, tissue fibrosis or
endothelialitis (histopathology score of 0) (Fig. 2a). Mice
receiving PBMC displayed a significant mononuclear cell
infiltration, especially surrounding the hepatic ducts with
endothelialitis (P < 0·0001) (Fig. 2a). MSC therapy on day 7
reduced liver pathology (P < 0·0086), with decreased cell
infiltration and reduced endothelialitis (Fig. 2a). Similarly,
the small intestines of PBS-treated control mice appeared
normal, with no sloughing of villi and no accumulation
of infiltrating cells into the lamina propria (Fig. 2b). In
comparison, NSG mice that received PBMC displayed
blunting of villi with cell infiltration into the lamina propria
and intestinal crypts (Fig. 2b) (P < 0·0001). This was
reduced significantly by human MSC therapy at day 7
(P < 0·0249). Control NSG mouse lungs appeared nor-
mal, but PBMC delivery provoked cellular infiltration/
inflammation (Fig. 2c) (P < 0·0002). In contrast to the pro-
tective effects in the liver and gut, treatment with MSC on
day 7 did not ameliorate pathology in the lungs compared
to aGVHD mice (Fig. 2c).
Stimulation of MSC with proinflammatory cytokines
such as IFN-g promotes the immunosuppressive capacity in
vitro and enhances their beneficial role in treating aGVHD
in vivo [32,36], a phenomenon termed ‘licensing’. Therefore,
MSC were stimulated in vitro with IFN-g (MSCg) for 48 h
prior to administration to NSG mice on day 0 in the
aGVHD model. MSCg therapy reduced aGVHD-related
weight loss and pathology (Fig. 1d,e), while significantly
increasing the survival time of mice with aGVHD
(P < 0·0015) in comparison to mice that had not received
MSC therapy (Fig. 1f). MSCg therapy on day 0 reduced
aGVHD pathology of the liver significantly (P < 0·0163),
reducing cell infiltration and endothelialitis (Fig. 2a). IFN-g
stimulated MSC also reduced gut pathology with reduced
cell infiltration and significantly less tissue damage to villi
(P < 0·0142) (Fig. 2b), similar in extent to non-stimulated
MSC therapy at day 7. However, as seen earlier, MSCg
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therapy did not ameliorate the pathology observed in the
lung (Fig. 2c).
Reduction of aGVHD following human MSC therapy
was not due to impaired engraftment or through the
induction of donor PBMC apoptosis or anergy
A simple explanation for the observation above could be
that human MSC therapy reduces human PBMC engraft-
ment in the NSG model. To exclude this possibility, the
numbers of human CD45+ cells and the ratios of CD4/CD8
T cells were investigated in the above model. IFN-g-
stimulated human MSC therapy on day 0 or non-
stimulated MSC therapy on day 7 did not affect the
engraftment of human CD45+ cells (Fig. 3a). Human CD4
and CD8 T cells were detectable in the spleens of NSG mice
following human PBMC infusion, but MSC therapy (IFN-
g-stimulated or not) did not prevent the engraftment of
human T cells or significantly alter the CD4 : CD8 ratio
(Fig. 3b). In support of this observation, the levels of
human IL-2 in the sera of NSG mice following PBMC infu-
sion was not significantly altered by MSC therapy (Fig. 3c),
indicating that MSC therapy did not hinder effector cell
engraftment.
The mechanism by which MSC therapy limited aGVHD
in this humanized mouse model might involve immuno-
logical tolerance, such as the induction of either donor
lymphocyte apoptosis or anergy. The ability of MSC to
induce apoptosis of T cells was investigated, both in vitro
and in vivo. The induction of PBMC apoptosis in vitro
by human MSC was examined using an MSC/PBMC
co-culture model. A known inducer of PBMC apoptosis,
cisplatin, caused significant apoptosis of PBMC (Fig. 4a),
whereas allogeneic human MSC did not (P < 0·0001)
(Fig. 4a). However, the lack of apoptosis in vitro might
not reflect the in vivo situation, therefore the NSG model
was adapted to detect apoptotic cells. NSG mice were
treated with PBS or PBMC, with or without MSCg cell
therapy on day 0. FLIVO (a reagent which detects active
caspases of apoptotic cells in vivo) was administered i.v. 12
days later and allowed to circulate for 1 h. After 1 h, the
lungs (Fig. 4b) and livers (Fig. 4c) were harvested and
analysed for FLIVO/CD4 staining by two-colour flow
cytometry. Although CD4+ T cells were detected, there
was no increase in apoptotic CD4+ T cells following
MSCg therapy in either organ sampled on day 12
(Fig. 4b,c) or at other times prior to day 12 (days 1 or 5,
data not shown). These data suggested that MSC did not
induce detectable apoptosis of donor human CD4+ T cells
in vivo or in vitro and that this was unlikely to be the
mechanism involved in the beneficial effect mediated by
MSC in this model.
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Fig. 1. Mesenchymal stem or stromal cell
(MSC) therapy significantly prolongs the
survival of non-obese diabetic (NOD) severe
combined immunodeficient (SCID) interleukin
(IL)-2rgnull (NSG) mice with acute
graft-versus-host disease (aGVHD). NSG mice
received 2·4 Gy low-dose irradiation; 4 h later
peripheral blood mononuclear cells (PBMC)
(6·3 ¥ 105 g-1) were administered intravenously
via the tail vein. Non-stimulated MSC were
administered on day 7 post-PBMC transfusion
or interferon (IFN)-g-prestimulated MSC
(MSCg) (4·4 ¥ 104 g-1) were delivered on day 0,
concurrent with PBMC. (a,d) Weight loss,
(b,e) aGVHD score and (c,f) survival were
recorded daily. Both non-stimulated and
IFN-g-stimulated MSC significantly prolonged
the survival of NSG mice with aGVHD
(P < 0·0001 and P < 0·0015, respectively),
limiting weight loss and reducing the clinical
signs of aGVHD development (n = 7 mice per
group). Data shown are representative of at
least two experiments.
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Fig. 2. Mesenchymal stem or stromal cells (MSC) cell therapy significantly reduces pathology in the liver and gut of non-obese diabetic (NOD)
severe combined immunodeficient (SCID) interleukin (IL)-2rgnull (NSG) mice with acute graft-versus-host disease (aGVHD). aGVHD was
established in NSG mice (as Fig. 1) and treated with non-stimulated MSC (day 7) or interferon (IFN-g)-stimulated MSC (day 0). The livers, small
intestine and lungs were harvested on day 12. (a) The livers of NSG mice displayed a significant increase in mononuclear cell infiltration (denoted by
arrow and letter a) and increased endothelialitis, especially around hepatic ducts (denoted by arrow and letter b). Both MSC and interferon
(IFN)-g-prestimulated MSC (MSCg) treatment significantly reduced this pathology. (b) aGVHD of the small intestine resulted in the accumulation
of infiltrating cells into the lamina propria (denoted by arrow and letter a) and increased blunting of the villi (denoted by arrow and letter b).
Similar to the liver, MSC or MSCg cell therapy resulted in a significant decrease of cell infiltration and villous blunting. (c) aGVHD development in
the lungs manifested by a significant increase of mononuclear cells into alveolar air spaces (denoted by arrow and letter a). Unlike the liver and small
intestine, treatment of aGVHD NSG mice with MSC or MSCg did not alleviate the symptoms of airway aGVHD. Bar charts in the right-hand panel
summarize histological scores. Data are representative of a minimum five mice per treatment group and at least two independent experiments.
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An alternative hypothesis for the beneficial effect of MSC
cell therapy was formulated around the induction of donor
T cell anergy. To examine this, an in vitro two-step prolifera-
tion assay was designed which would closely mimic in vivo
circumstances. First, murine DC isolated from the bone
marrow of BALB/c mice were used to mimic the murine
(host) antigen-presenting cell. These were matured using
polyIC as a stimulus and co-cultured with human CD4+ T
cells for 5 days in the presence or absence of MSC. After 5
days, the proliferation of human CD4+ T cells was analysed.
Human CD4+ T cells proliferated strongly when cultured
with mature murine DC (P < 0·0001); however, allogeneic
human MSC significantly reduced this effect (P < 0·05)
(Fig. 5a). These data showed that MSC were capable of
inhibiting T cell proliferation in a xenogeneic setting, analo-
gous to that found in the aGVHD NSG model. To examine
if the reduction in T cell proliferation by MSC was due to
the induction of T cell anergy, a two-stage assay was then
performed. Human CD4+ T cells were co-cultured with
mature murine DC and/or MSC for 5 days; human CD4+ T
cells were re-isolated from cultures by magnetic bead isola-
tion. Re-isolated CD4+ T cells were allowed to rest overnight
then cultured for a second time with irradiated BALB/c DC
stimulated with or without polyIC/IL-2. Following the
second-stage co-culture, human CD4+ T cells proliferated in
response to irradiated mature DC (Fig. 5b). The prolifera-
tion of CD4+ T cells that had been previously cultured in
the presence of MSC was not significantly different. Fur-
thermore, the addition of IL-2 did not alter the prolifera-
tion of human CD4+ T cells, suggesting that MSC did not
induce T cell anergy in vitro (Fig. 5c). These data suggested
that the beneficial effects seen in vivo following MSC
therapy were not due to donor T cell apoptosis or anergy
but to some other mechanism.
Allogeneic human MSC-induced regulatory-like T cells
expressing FoxP3 in vitro, but not in vivo, in the NSG
aGVHD model
Previous studies of cell therapy in other models have shown
that the MSC-driven induction of FoxP3-expressing Treg
cells are responsible for some of the beneficial effects of
MSC in vivo [22,37]. The induction/expansion of Treg fol-
lowing MSC therapy was therefore examined as a possible
mechanism involved in the therapeutic effect. First, human
MSC were tested for the ability to expand FoxP3+ Treg cells
in vitro from a whole population of allogeneic PBMC
(Fig. 6a). After co-culture with MSC for 72 h in vitro,
PBMC were analysed for the co-expression of CD4, CD25
and intracellular FoxP3. MSC expanded a CD4+ Treg-like cell
population expressing FoxP3 and CD25 in vitro (Fig. 6a), in
agreement with our previous work [16]. An examination of
sorted CD4+CD25+ and CD4+CD25- T cells showed that
MSC did not induce FoxP3+ populations de novo from
CD4+CD25- cells, but rather expanded a pre-existing popu-
lation of FoxP3+ Treg cells (Fig. 6b). Following this observa-
tion, Treg cell expansion by MSC and MSCg was explored in
the NSG model of aGVHD. On day 12 (the typical onset
day of aGVHD pathology), the lungs, livers and spleens
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engraftment. Interferon (IFN)-g-stimulated (day 0) or non-stimulated
MSC (day 7) (4·4 ¥ 104 g-1) were administered to irradiated non-obese
diabetic (NOD) severe combined immunodeficient (SCID) interleukin
(IL)-2rgnull NSG mice that had received PBMC (6·3 ¥ 105 g-1) on day 0
(n = 5 per group). The spleens of the NSG mice from each treatment
group were harvested on days 4, 8 and 12 and analysed for the
expression of (a) human CD45+ and (b) the ratio of human CD4 to
CD8 T cells by flow cytometry. Human PBMC engrafted readily, with
a significant increase in CD45+ cells from days 4 to 8 (P < 0·05) and 12
(P < 0·002) compared to controls. MSC therapy had no significant
effect on the engraftment of human PBMC. The number of CD45+
cells per 105 total splenocytes was enumerated using counting beads.
(c) The level of human IL-2 present in the sera of mice from each
treatment group was analysed by cytokine bead array. MSC therapy
had no effect on the amount of human IL-2 detectable in sera.
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were harvested and analysed for the presence of human cells
expressing CD4, CD25 and/or Foxp3 by flow cytometry
(Fig. 6c–e). There was no evidence of expansion of
CD4+CD25+FoxP3+ T cell populations in vivo (Fig. 6c–e),
even though we have detected MSC expansion of Treg previ-
ously using these methods [37]. Treg expansion could not be
detected following treatment with either non-stimulated
MSC on day 7 or MSCg on day 0 in the lungs (Fig. 6c),
livers (Fig. 6d) or spleens (Fig. 6e). These data suggested
that in this model, MSC expansion of CD4+CD25+FoxP3+
Treg-like cells was unlikely to be the mechanism involved in
prolonged survival following cell therapy.
Allogeneic MSC directly inhibited the proliferation of
donor CD4+ T cells in vivo
It is well documented that MSC have the ability to directly
suppress T cell proliferation in vitro [16,20,36,38]. There-
fore, it was possible that the beneficial effect of MSC
therapy in the NSG model of aGVHD could be attributed
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to a direct anti-proliferative effect on donor T cells in vivo.
To explore this, MSC were first examined to verify the in
vitro suppression of PBMC proliferation. Human
MSC inhibited the proliferation of alloantigen-driven
and mitogen-driven proliferation of PBMC (Fig. 7a,b)
(P < 0·0001). This inhibition was associated with a signifi-
cant decrease in both IFN-g (Fig. 7c,d) (P < 0·0001) and
TNF-a (Fig. 7e,f) (P < 0·0201 and P < 0·0001, respectively)
present in culture supernatants. These data suggested that
MSC might have a similar effect in vivo, suppressing the
development of aGVHD.
To investigate the influence of MSC on proliferation of
donor PBMC in vivo, conditioned NSG mice received
CFSE-labelled PBMC with or without MSCg treatment
concurrently on day 0. In this instance, MSCg therapy was
chosen in preference to MSC therapy to allow a directly
aligned comparison on T cell proliferation over time. Mice
were left for 5 days before analysing the effect of MSCg
treatment on PBMC proliferation. Lungs, livers and spleens
were harvested and the fluorescence of CFSE+ labelled CD4+
T cells was analysed by flow cytometry (Fig. 8a). CFSE-
labelled PBMC were detected in the lungs of NSG on day 5,
but sufficient cells could not be recovered from other
organs at this time-point, consistent with the cell infiltra-
tion evident in this model (Fig. 2c and data not shown).
MSCg-treated mice had significantly fewer CD4+ T cells
progressing to division (P < 0·0041) when compared to
mice that received PBMC alone on day 0 (Fig. 8a,b). MSCg
therapy also significantly reduced the absolute number of
divisions underwent by human CD4+ T cells (P < 0·0037)
(Fig. 8b). This reduction in T cell proliferation could not be
due to the inhibition of human T cell chimerism within the
model following MSC therapy, as not only did human T
cells readily engraft, but MSC therapy did not prevent this T
cell engraftment (Fig. 3). Interestingly, these data also
revealed that aGVHD development in this humanized
mouse model was associated with CD4+ rather than CD8+ T
cell expansion in vivo (Fig. 8).
Serum was harvested from all NSG mice at the time of
aGVHD development (day 12) and analysed for the pres-
ence of human IFN-g and TNF-a. As expected, NSG mice
that received PBMC had significantly more human TNF-a
present in the serum after 12 days when compared to PBS
controls (Fig. 8c, P < 0·0027). MSCg cell therapy signifi-
cantly reduced human TNF-a (Fig. 8c, P < 0·0197), but had
no significant effect on the presence of human IFN-g in the
serum of NSG mice (Fig. 8d). Collectively, these data
suggest that MSC cell therapy in this model acts through
the direct suppression of donor T cell proliferation, limiting
aGVHD pathology in vivo and reducing TNF-a, a key CD4+
T cell-derived effector molecule in aGVHD [2,39].
Discussion
In this study, a humanized mouse model of aGVHD was
developed that allowed the reproducible assessment of
human cell therapeutics. Allogeneic human MSC therapy
given on day 7 or IFN-g stimulated MSC on day 0 increased
the survival of NSG mice with aGVHD. Therapeutic effects
of MSC were significant in the liver and gut of mice with
aGVHD, but were not effective in the lung. Examinations of
the mechanisms of therapeutic action by MSC in this model
revealed that protection was not associated with MSC
induction of donor T cell apoptosis, the induction of donor
T cell anergy or prevention of donor cell engraftment.
Unlike other models, protection against aGVHD was not
linked to MSC-driven expansion of Treg populations, but
rather the direct suppressive effect on donor T cell prolif-
eration and reduction of T cell-derived human TNF-a. This
model mimics closely the data seen from recent clinical
trials and offers a system in which mechanisms of action
may be explored.
The key to improving current cell therapies for aGVHD
is an understanding of the mechanisms of cell action. The
humanized mouse model described here provides a refined
tool to test human cell therapies and their mechanisms of
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action. Animal models of GVHD have well-known limita-
tions, especially with regard to assessment of human cell
therapies. For example, Sudres et al., using a model where
C57BL/6 bone marrow cells were injected into lethally irra-
diated BALB/c mice, found that murine MSC therapy had
no beneficial effect on survival [40]. Jeon et al. found that
human MSC were unable to prevent GVHD development
and the symptoms of GVHD were not alleviated in vivo
[41], the drawback of the latter system being the mismatch
between human MSC and murine effector cells (murine as
Fig. 6. Human mesenchymal stem or stromal cells (hMSC) supported the expansion of CD4+ CD25+ forkhead box protein 3 (FoxP3)+ T cells in
vitro but not in vivo. Expression of FoxP3 was measured in vitro (a,b) and in vivo (c–e). In vitro, (a) peripheral blood mononuclear cells (PBMC) or
(b) sorted human CD4+ CD25+ or CD4+ CD25- T cells (0·5 ¥ 106/ml) were co-cultured with or without MSC (1·5 ¥ 105/ml) for 72 h. Cells were
recovered and examined for the expression of CD4, CD25 (PBMC population) and FoxP3 by intracellular flow cytometry. (a) The percentage of
double-positive PBMC expressing CD4/CD25 or CD4/FoxP3 is given in the upper quadrant. (b) The number of FoxP3-expressing CD4 cells sorted
from whole PBMC is represented in the bar chart. MSC did not induce a population of FoxP3+ regulatory T cells (Treg) cells, but rather expanded
an already existing population in vitro (data are representative of three independent experiments). In-vivo non-obese diabetic (NOD) severe
combined immunodeficient (SCID) interleukin (IL)-2rgnull NSG mice received phosphate-buffered saline (PBS) or PBMC (6·3 ¥ 105 g-1) on day 0
with or without non-stimulated MSC on day 7 or interferon (IFN)-g-prestimulated MSC (MSCg) on day 0 (4·4 ¥ 104 g-1). On day 12, the (c) lungs,
(d) livers and (e) spleens were harvested and analysed for the expression of human CD4, CD25 and FoxP3 by flow cytometry. Data are summarized
in bar charts in the right-hand panels. CD4+ FoxP3+ Treg-like cells were not detected in vivo following MSC therapy. In this instance data are
representative of six mice per group (n = 6).
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Fig. 7. Mesenchymal stem or stromal cells
(MSC) inhibit peripheral blood mononuclear
cell (PBMC) proliferation and suppress
interferon (IFN)-g and tumour necrosis factor
(TNF)-a production in vitro. (a) PBMC
(1 ¥ 106/ml) from two major histocompatibility
complex (MHC) mismatched donors (D1 or
D2) were cultured in the presence or absence of
MSC (1 ¥ 105/ml) in a mixed lymphocyte
reaction (MLR). MSC inhibited
alloantigen-driven proliferation significantly
(P < 0·0001). (b) Human MSC also suppressed
mitogen [phytohaemagglutinin(PHA)]-driven
proliferation of allogeneic human PBMC
(P < 0·0001) in vitro. The inhibition of
proliferation correlated with a significant
decrease in the production of (c,d) IFN-g
(P < 0·0001) and (e,f) TNF-a (P < 0·0201,
P < 0·0001, respectively), as measured by
enzyme-linked immunosorbent assay. Data are
representative of three experiments, each
performed in triplicate.
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opposed to human graft). In the model described here, the
effector cells are those deployed in human recipients and
the MSC may be sourced from production batches intended
for clinical use. Thus, this model offers a system to evaluate
batches of MSC therapeutics against the donor lymphocytes
to be used clinically.
The observation that the kinetics of therapeutic delivery
had a profound outcome on survival was not surprising.
Polchert et al. found no significant improvement in
aGVHD-related mortality when murine MSC were given as
a therapy on day 0, but treatment with MSC on days 2 or 20
post-bone marrow transplantation prolonged the survival
of mice with aGVHD [32]. In order for human MSC cell
therapy to be beneficial at day 0, MSC required stimulation
or activation with IFN-g (Fig. 1). These results were similar
to those of other studies [32,42,43], suggesting that MSC
require prestimulation or ‘licensing’ with IFN-g for efficacy
at the earliest time-points [32]. The failure of non-
stimulated MSC to treat aGVHD when delivered concur-
rently with donor PBMC is interesting. Normally, IFN-g
enhances allogenicity; however, MSC stimulated with IFN-g
show enhanced immunosuppressive ability [36,44,45]. As
GVHD develops in this model, the levels of IFN-g increase.
It may be that sufficient levels of IFN-g are required for the
activation of non-stimulated MSC [32]. Therefore, MSC
administered after the development of a proinflammatory
environment in vivo are more successful in prolonging the
survival of mice with GVHD than those delivered at day 0.
These data highlight the importance of cell manipulation as
well as timing in designing MSC therapeutic protocols.
The humanized model used here allowed for the success-
ful engraftment of human cells (Fig. 3). This engraftment of
human CD45+ cells was not hindered by MSC therapy, but
both non-stimulated (at day 7) and IFN-g-stimulated MSC
therapies significantly reduced the severity of aGVHD
pathology in the small intestines and livers of NSG mice
after 12 days (Fig. 2). Human MSC therapy reduced villous
blunting and lymphocyte infiltration into the lamina
propria of the small intestine, while reducing vascular
endothelialitis and lymphocyte infiltration into the paren-
chyma of the liver. These data were similar to Polchert et al.
and Joo et al., where murine MSC therapy significantly
improved the histological score of the intestine and liver of
mice with GVHD [32,42]. Unlike Polchert et al., human
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Fig. 8. Mesenchymal stem or stromal cells (MSC) reduced the proliferation of CD4+ T cells and suppressed tumour necrosis factor (TNF)-a
production in vivo. Peripheral blood mononuclear cells (PBMC) labelled with 10 mM carboxyfluorescein succinimidyl ester (CFSE) were
administered to conditioned non-obese diabetic (NOD) severe immunodeficient interleukin (IL)-2rgnull NSG mice with or without interferon
(IFN)-g-prestimulated MSC (MSCg) on day 0. After 5 days, the lungs, livers and spleen were harvested. (a) The level of CFSE in CD4+ T cells was
analysed by flow cytometry. MSC reduced the proliferation of CD4+ T cells in the lung at 5 days. Sufficient CFSE-stained CD4+ T cells were not
recoverable from the livers or spleen after 5 days. (b) The percentage of CD4+ cells present in the lung at each division in vivo. Serum was taken from
NSG mice on day 12 and analysed for the presence of (c) human TNF-a and (d) human IFN-g by bead array. Prestimulated MSCg reduced
significantly the level of (c) human TNF-a (P < 0·0267) in the sera of NSG mice with acute graft-versus-host disease (aGVHD). Human MSC
(hMSC) therapy had no significant effect on (d) human IFN-g production in sera. Data are representative of five mice per group (n = 5).
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MSC therapy did not improve the histological analysis of
the lung in NSG mice with aGVHD, as there was a signifi-
cant amount of cell infiltration in all treatment groups
(Fig. 2). Importantly, the histological results herein mir-
rored those of a recent Phase III human clinical trial [27].
This trial set out to examine the effects of human MSC,
Prochymal®, in the treatment of patients with steroid-
refractory aGVHD. Although Prochymal® cell therapy was
well tolerated in patients with no adverse effects in a Phase
II trial [25], findings of a Phase III trial have been difficult
to interpret mechanistically. In the Phase III clinical trial,
patients who presented with aGVHD manifesting in the
liver and the gut showed significant improvement following
treatment, similar to that seen here. However, cell therapy
had no beneficial effect on skin manifestations. Although
histological analysis of the skin was not examined in the
humanized model, the beneficial effect of MSC-based cell
therapy here was also target organ-dependent. This might
be linked to MSC localization to different target organs, a
hypothesis testable in the model we describe.
The major benefit of this model is that it allows a mecha-
nistic exploration of MSC therapy not possible in patients,
and specifically the link between MSC therapy and immu-
nological tolerance. The induction of immune tolerance
involves a precise balance between activation and inhibition
of T cell responses, which is important in the development
of GVHD. Tolerance can occur through the induction of
lymphocyte apoptosis, anergy, regulatory cell induction/
expansion or the direct inhibition of lymphocyte prolifera-
tion. Several studies have given contradictory evidence in
relation to the induction of T cell apoptosis by MSC
[46,47]. In this study, MSC did not induce apoptosis of
PBMC in vitro (Fig. 4) or suppress engraftment (Fig. 3).
MSCg therapy to NSG mice with aGVHD did not increase
the number of detectable apoptotic cells after 12 days
(Fig. 4). These data are in line with other groups reporting
that MSC play no role in the induction of T cell apoptosis
[17,18,47,48], but are in contrast to Plumas et al., who
found that human MSC induced the induction of apoptosis
of activated T cells through the production of indoleamine-
2,3-dioxygenase (IDO) [46]. Despite the contradictory lit-
erature, the data herein indicated that the induction of T
cell apoptosis by MSC was unlikely to be the mechanism by
which MSC prolonged the survival of NSG mice with
aGVHD.
The concept that MSC induce T cell anergy has also been
controversial [47,49]. Studies of bone marrow-derived
murine MSC co-cultures have resulted in T cells that did
not regain their ability to proliferate in response to the
cognate antigen, reversible by the addition of IL-2, suggest-
ing the induction of T cell anergy [47,49]. The findings here
suggested that MSC did not induce CD4+ T cell anergy in
vitro. Using a classical two-step assay, human MSC inhibited
the proliferation of allogeneic human CD4+ T cells follow-
ing stimulation by murine DC. Upon restimulation of puri-
fied CD4+ T cells (with irradiated murine DC in the
presence or absence of IL-2), T cell proliferation was unal-
tered (Fig. 5). This suggested that MSC did not induce an
antigen-specific anergic T cell population. In other murine
and human studies, T cell unresponsiveness was shown as
transient and reversible if MSC were removed from cul-
tures, suggesting a more direct suppressive effect than
classical anergy [17,50]. While it is difficult to make com-
parisons across diverse experimental systems, the data from
this system do not support an interpretation that MSC
evoke classical T cell anergy in this model.
CD4+CD25+FoxP3+ Treg cells play a role in the induction
and maintenance of immune tolerance [51]. Many murine
studies have identified a correlation between Treg cells and
the induction, acceleration and treatment/prevention of
aGVHD [52–54]. It is well documented both here (Fig. 6)
and by others that MSC are capable of expanding Treg-like
cell populations in vitro [16,55,56]. The deletion of
CD4+CD25+ Treg cells from bone marrow grafts prior to
transplantation dramatically accelerates aGVHD develop-
ment in other murine models [52,57,58]. Additionally, the
infusion of ex-vivo-expanded CD4+CD25+FoxP3+ Treg cells
prevents aGVHD development, while preserving graft-
versus-leukaemia (GvL) activity [53,54,58–60]. This inverse
correlation between Treg cells and aGVHD has also been
seen in patients with aGVHD [61]. We were surprised to
find that non-stimulated or IFN-g-stimulated MSC cell
therapy did not result in increased CD4+CD25+FoxP3+ T
cells in the lung, liver or spleens of NSG mice with aGVHD,
especially as we have detected these cells in other disease
systems [37]. These findings are also in contrast with work
published by other groups in different systems [42,62].
The data here may have multiple causes. It may be that as
MSC expand but do not induce Treg, the lack of such
populations here reflects the low frequency of Treg in the
initial donor PBMC populations. Thus, the numbers of
CD4+CD25+FoxP3+ T cells present in the donor PBMC were
too low for their expansion following MSC transfusion in
vivo. Alternatively, it may reflect a more fundamental issue
with NSG mice and a limitation of our model. It could be
that the absence of human stromal factors to support the
expansion of human Treg cells in the NSG mouse model of
aGVHD or that other non-conventional FoxP3 Treg popula-
tions are involved. A related feature is that in NSG mice
(even with aGVHD), lymph nodes are vestigial and the
stromal compartment may not be sufficient for Treg cells
to develop effectively in this system. Interestingly, MSC
therapy prolonged the survival of NSG mice with aGVHD
but did not prevent aGVHD development in the longer
term (as seen in clinical trials also) [25,27]. If Treg cells had
been induced or expanded a more permanent suppression
might be expected, which would suggest that MSC therapy
as a single dose has a more transient/limiting effect on
aGVHD development, rather than induction of immune
tolerance, as has been suggested previously [43].
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MSC inhibition of T cell proliferation in vitro is well
documented [16,17,47,49], but there are contradictory data
available for the inhibition of T cell proliferation by MSC in
vivo [40,47]. Sudres et al. found that although murine MSC
inhibited the proliferation of T cells in vitro, administration
on day 1 to treat GVHD had no effect on the proliferation
of CFSE-labelled T cells in vivo [40], others have also shown
that although murine MSC could inhibit T cell proliferation
in vitro, this was not detectable in vivo [43]. We could not
detect suppression in the liver or spleen in the NSG model
of aGVHD due to the very low recovery of T cells from
MSC-treated mice. However, in the lungs, the organ with
the greatest inflammatory manifestation, IFN-g stimulated
MSC therapy resulted in the reduction of CD4+ T cell pro-
liferation in NSG mice after 5 days (Fig. 8). These data
showed that MSC inhibition of T cell proliferation and
reduction in serum TNF-a are features of MSC-mediated
immune suppression in vivo. Although these data suggest
that the suppression of T cell proliferation/activation is the
primary mechanism of human MSCg therapy, it is impor-
tant to note that stimulated and non-stimulated MSC may
work in different ways, and this requires further investiga-
tion. None the less, these data highlighted a possible mecha-
nism by which MSC cell therapy prolonged the survival of
NSG mice with aGVHD and suggests that improvements to
MSC therapy are amenable to exploration in the model
described herein.
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